[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342971-105":3,"doc-detail-342971-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","metabolic-reprogramming-in-thyroid-cancer-review","Metabolic Reprogramming in Thyroid Cancer - Review","","Metabolic Reprogramming in Thyroid Cancer is a review article examining how thyroid cancer metabolism can be leveraged for more effective treatment. It outlines the clinical burden of thyroid cancer and the limits of existing targeted therapies, including RET and BRAF kinase inhibition, which can be constrained by resistance mechanisms. The review emphasizes how cancer cells exploit metabolic plasticity and summarizes research on metabolic inhibitors and combinatorial strategies that pair metabolic targeting with targeted therapy, chemotherapy, and immunotherapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/metabolic-reprogramming-in-thyroid-cancer-review/342971/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/metabolic-reprogramming-in-thyroid-cancer-review/342971.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is thyroid cancer treatment challenging even though many cases are treatable?","Question",{"text":63,"@type":64},"Most thyroid cancer cases have a favorable prognosis, but a subset is more aggressive and carries higher mortality risk. Resistance mechanisms can also limit the effectiveness of kinase inhibitors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What therapeutic strategy does the review highlight for advanced or aggressive thyroid cancer?",{"text":68,"@type":64},"Inhibiting RET and BRAF kinases is presented as a potential therapeutic strategy, especially for advanced or aggressive disease. The review also discusses overcoming resistance through metabolic targeting.",{"name":70,"@type":61,"acceptedAnswer":71},"How does metabolic plasticity relate to developing effective cancer therapies?",{"text":72,"@type":64},"The review explains that metabolic plasticity enables cancer cells to adapt, making it harder to sustain therapeutic effects. It argues that combining metabolic inhibition with other treatment modalities may improve strategy effectiveness.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342971,1790449701,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780",8,"Review Article  \nEndocrinol Metab 2024;39:425-444 [https://doi.org/10.3803/EnM.2023.1802](https://doi.org/10.3803/EnM.2023.1802)[ ](https://doi.org/10.3803/EnM.2023.1802)[pISSN 2093-596X](pISSN 2093-596X) · eISSN 2093-5978  \nMetabolic Reprogramming in Thyroid Cancer  \nSang-Hyeon Ju 1, Minchul Song1, Joung Youl Lim1, Yea Eun Kang1,2, Hyon-Seung Yi1,2, Minho Shong3  \n1Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University Hospital; 2Department of Internal Medicine, Chungnam National University College of Medicine; 3Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea  \nThyroid cancer is a common endocrine malignancy with increasing incidence globally. Although most cases can be treated effectively, some cases are more aggressive and have a higher risk of mortality. Inhibiting RET and BRAF kinases has emerged as a potential therapeutic strategy for the treatment of thyroid cancer, particularly in cases of advanced or aggressive disease. However, the development of resistance mechanisms may limit the efficacy of these kinase inhibitors. Therefore, developing precise strategies to target thyroid cancer cell metabolism and overcome resistance is a critical area of research for advancing thyroid cancer treatment. In the field of cancer therapeutics, researchers have explored combinatorial strategies involving dual metabolic inhibition and metabolic inhibitors in combination with targeted therapy, chemotherapy, and immunotherapy to overcome the challenge of metabolic plasticity. This review highlights the need for new therapeutic approaches for thyroid cancer and discusses promising metabolic inhibitors targeting thyroid cancer. It also discusses the challenges posed by metabolic plasticity in the development of effective strategies for targeting cancer cell metabolism and explores the potential advantages of combined metabolic targeting.  \n\n| Keywords: Thyroid neoplasms; Tyrosine kinase inhibitors; Drug resistance, neoplasm; Metabolic networks and pathways; Immunotherapy |  |\n| --- | --- |\n| INTRODUCTION\u003Cbr>Thyroid cancer is a common endocrine malignancy that originates from the thyroid gland. The incidence of thyroid cancer has been increasing globally in the past few decades, with an estimated 567,000 new cases and 41,000 deaths in 2020 [1] . The exact causes of thyroid cancer remain elusive, but several risk factors have been identified. The most well-established risk factor for thyroid cancer is exposure to ionizing radiation, particularly during childhood [2] . Other factors that have been associated with an increased risk of thyroid cancer include a family history of the disease, the presence of certain variants in susceptibility genes, such as WD repeat domain 77 (WDR77), BRO1 | domain and CAAX motif containing (BROX), hyaluronan binding protein 2 (HABP2), and SLIT-ROBO Rho GTPase activating protein 1 (SRGAP1) for papillary thyroid cancer (PTC), and forkhead box E1 (FOXE1) for both PTC and follicular thyroid cancer (FTC), and certain benign thyroid conditions such as goiter and thyroid nodules [2,3] . PTC is the most common typeof thyroid cancer, accounting for 80% to 85% of cases. FTC is the second most common type, representing 10% to 15% of cases, followed by medullary thyroid cancer (MTC) and anaplastic thyroid cancer (ATC), which account for 3%–5% and 1%–2% of cases, respectively [4] . Most cases of thyroid cancer have a favorable prognosis and can be effectively treated, but some cases are more aggressive and have a higher risk of mor- |\n| Received: 15 August 2023, Revised: 25 January 2024, Accepted: 12 March 2024\u003Cbr>Corresponding author: Minho Shong\u003Cbr>Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Korea Tel: +82-42-350-0236, Fax: +82-42-280-6990, [E-mail:](E-mail: minhos@kaist.ac.kr)[ minhos@kaist.ac.kr](E-ma","cbCaiklyqiqdGDXa","https://ap.wps.com/l/cbCaiklyqiqdGDXa","pdf",1983435,20,"English","# Introduction\n## Epidemiology and risk factors\n## Molecular drivers and tumor types\n# Targeted therapy and resistance background\n## RET/BRAF kinase inhibition and resistance","[{\"question\":\"Why is thyroid cancer treatment challenging even though many cases are treatable?\",\"answer\":\"Most thyroid cancer cases have a favorable prognosis, but a subset is more aggressive and carries higher mortality risk. Resistance mechanisms can also limit the effectiveness of kinase inhibitors.\"},{\"question\":\"What therapeutic strategy does the review highlight for advanced or aggressive thyroid cancer?\",\"answer\":\"Inhibiting RET and BRAF kinases is presented as a potential therapeutic strategy, especially for advanced or aggressive disease. The review also discusses overcoming resistance through metabolic targeting.\"},{\"question\":\"How does metabolic plasticity relate to developing effective cancer therapies?\",\"answer\":\"The review explains that metabolic plasticity enables cancer cells to adapt, making it harder to sustain therapeutic effects. It argues that combining metabolic inhibition with other treatment modalities may improve strategy effectiveness.\"}]","Metabolic Reprogramming in Thyroid Cancer - Review | PDF",1790049207,50,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52ebde9f03cfe6022c2afbfe00e1430d.webp",983,1310,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d09df701b8df22943e5b861e6fcd72b.webp",982,1309,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6472bcc6d5268543ac34cda6bfab897.webp",981,1308,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21b5d48dd742855d147c0387915033c3.webp",980,1306,{"code":4,"msg":82,"data":117},[118,122,126,130,135,139,144,147,151,154,157],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":98,"slug":138},6,"Technology","technology",{"id":140,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":142,"slug":143},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":145,"slug":146},30,"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":92,"slug":150},9,"Religion & Spirituality","religion-spirituality",{"id":92,"doc_module":4,"doc_module_name":25,"category_name":152,"show_sort_weight":92,"slug":153},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":155,"show_sort_weight":55,"slug":156},"Lifestyle","lifestyle",{"id":158,"doc_module":4,"doc_module_name":25,"category_name":159,"show_sort_weight":131,"slug":160},19,"General","general"]